News and Trends 18 Nov 2022
NW Bio reports positive top-line results from phase 3 glioblastoma trial
Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November 17) reported that both median and long tail survival were increased in both newly diagnosed…